Aller au contenu principal
Profil bibliographique

Brady Bernard

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

6Publications signalées
9433Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Ferroptosis and cancer prognosisCancer Immunotherapy and BiomarkersSarcoma Diagnosis and TreatmentEpigenetics and DNA MethylationColorectal Cancer Surgical Treatments

Les publications récentes

Accès ouvert 2026 article OpenAlex

A tailored in vivo CRISPR screen identifies BAP1 as a potent tumor suppressor of sarcoma

Jianguo Huang, Xingliang Liu, Warren Floyd, William Haugh et autres

Undifferentiated pleomorphic sarcoma (UPS) is one of the most common adult soft-tissue sarcomas (STSs), yet therapeutic progress remains limited because of the absence of recurrent oncogenic driver mutations. To identify tumor suppressors contributing to UPS pathogenesis, we performed a customized in vivo …

us, cn, ca (code pays fourni par la source)

0 citations JCI Insight
2026 conference-abstract OpenAlex

Abstract LB425: Search for targets of anti-cancer immunity in patients receiving an off-the-shelf cancer’s dark matter vaccine, DPV-001, combined with anti-PD-1 +/- anti-GITR in head and neck squamous cell cancer (HNSCC)

Traci L. Hilton, Ryan Meng, Guo Hui Gan, Tarsem Moudgil et autres

Abstract Background: Despite advances in cancer genomics and immunotherapy, most cancer vaccine strategies target a limited set of canonical or mutated cancer antigens, capturing only a fraction of tumor antigenicity. Malignant cells generate a vast, largely unexplored repertoire of non-canonical “dark matter” …

us, jp (code pays fourni par la source)

0 citations Cancer Research
Accès ouvert 2026 article OpenAlex

CMS subtypes correlate with complete response in trial of neoadjuvant Galunisertib plus chemoradiation in rectal cancer

Venkatesh Rajamanickam, Noah D. Simons, Wesley K. Rosales, Anton Kravchenko et autres

Improving responses to neoadjuvant therapy for patients with locally advanced rectal cancer has the potential to improve organ preservation and disease-free survival. Knowing which patients may need therapeutic escalation or de-escalation from standard-of-care treatment remains an area of investigation. We previously reported …

us, gb, co (code pays fourni par la source)

0 citations Translational Oncology
Accès ouvert 2018 article OpenAlex

The Immune Landscape of Cancer

Vésteinn Thórsson, Vésteinn Thorsson, David L. Gibbs, Scott D. Brown et autres

We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we identified six immune subtypes-wound healing, IFN-γ dominant, inflammatory, lymphocyte depleted, immunologically quiet, and TGF-β dominant-characterized by …

us, ca, es, be, qa, br (code pays fourni par la source)

6328 citations Immunity
Accès ouvert 2014 article OpenAlex

Comprehensive molecular characterization of urothelial bladder carcinoma

John N. Weinstein, Rehan Akbani, Bradley McIntosh Broom, Wenyi Wang et autres

Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. So far, no molecularly targeted agents have been approved for treatment of the disease. As part of The Cancer Genome Atlas project, we report here …

us, ca (code pays fourni par la source)

3108 citations Nature

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.